After witnessing a rise from $209.54 on February 8 to a high of $372.61 on September 28, Illumina (ILMN) stock corrected to $289.50 on October 24. Subsequently, Illumina stock recovered to $342.68 on November 7 but gave up the gains and fell to $301.08 on November 20.
Since then, Illumina stock has seen buying interest and is currently trading at $334.2.
Illumina’s revenue rose 19.47% from $714.0 million in the third quarter of 2017 to $853.0 million in the third quarter of 2018. The company’s revenue in the fourth quarter is expected to be $859.5 million.
Its gross margin expanded from 68.8% in the third quarter of 2017 to 71.16% in the third quarter of 2018. Further, for 2018 and 2019, Illumina’s gross margins are expected to be 70.16% and 70.23%, respectively.
From $725.0 million in 2017, the company’s net income is expected to rise to $796.23 million in 2018 and $877.18 million in 2019.
In December, of the 19 analysts covering Illumina, 14 have given the stock “buy” or higher ratings, and five have given it “hold” ratings. The mean rating for Illumina is 1.95, and its target price is $361.56, implying a potential upside of 8.2% over its closing price of $334.21 on December 4.
In the next article, we’ll explore the price performance of Intuitive Surgical.